Method for evaluating tigecycline ventricular injection administration effectiveness based on Monte Carlo simulation
Through Monte Carlo simulation and PK/PD model, the tigecycline ventricular injection scheme was evaluated using fCmax/MIC indicators, which solved the problem that tigecycline was difficult to cross the blood-brain barrier and provided effective administration for intracranial infections. The treatment effect was significantly improved.
Patent Information
- Application Number
- CN202410918058.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-10
- Publication Date
- 2024-11-12
AI Technical Summary
Tigecycline is difficult to pass through the blood-brain barrier, resulting in poor efficacy against intracranial infections. There are currently no objective indicators to evaluate the effectiveness of ventricular injection dosing regimens, especially for specific minimum inhibitory concentrations.
Monte Carlo simulation combined with PK/PD model was used to evaluate the effectiveness of tigecycline ventricular injection dosing regimens through fCmax/MIC indicators, determine the optimal concentration and frequency of dosing regimens, and use WHONET and Oracle Crystalball software for simulation and Data analysis.
An effective dosing regimen for intracranial infection was provided, which reduced the mortality rate of patients. Specific dosing regimens such as 2mg/12 hours, 3mg/12 hours and 5mg/12 hours were recommended, and the drug concentration was not more than 1mg/mL. Significantly improves the therapeutic effect.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure FDA0004935744080000011
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmacokinetics and pharmacodynamics models, and particularly relates to a method for evaluating the effectiveness of intraventricular injection of tigecycline based on Monte Carlo simulation. Background Art
[0002] Tigecycline is the first drug in the glycylcycline class to be used clinically. It has very high activity against Gram-positive or Gram-negative aerobic bacteria, atypical pathogens, and anaerobic bacteria, and has a strong inhibitory effect on a variety of drug-resistant bacteria. It is a key drug for the clinical treatment of infection. However, when administered by systemic intravenous infusion, it has a wide tissue distribution and is difficult to pass through the blood-brain barrier. The drug concentration in brain tissue and cerebrospinal fluid is low, and it may not reach an effective therapeutic concentration, making it less effective for intracranial infection.
[0003] Whether the drug can pass through the blood-brain barrier is an important factor affecting the efficacy of intracranial infection. For intracranial infection caused by multidrug-resistant bacteria for which intravenous administration of antibiotics alone is ineffective, if the minimum inhibitory concentration (MIC) of the drug is high, or it is difficult to cross the blood-brain barrier and cannot reach an effective therapeutic concentration, choosing a drug administration method such as intraventricular injection or intrathecal injection can bypass the blood-brain barrier and allow the drug to quickly reach an effective therapeutic concentration in the cerebrospinal fluid, thereby achieving the goal of effective treatment.
[0004] Studies have shown that the use of intraventricular injection of tigecycline to treat intracranial infection can reduce the mortality rate of patients by about 84%. It is an effective way to increase the clinical cure rate, and the safety of the central nervous system is also good. Therefore, the administration of tigecycline via intraventricular injection is increasingly being used in the treatment of intracranial infection. However, there is no consensus on the optimal administration method of tigecycline via intraventricular injection (including drug concentration, single dose, frequency of administration, etc.), and there is no objective indicator to evaluate the effectiveness of the dosing regimen for a specific minimum inhibitory concentration.
[0005] In clinical research on antimicrobial drugs, Monte Carlo simulation (MCS) and PK / PD models are often used to evaluate dosing regimens, thereby achieving accurate and effective treatment. Monte Carlo simulation, also known as random sampling or statistical test methods, is a branch of computational mathematics. It is a computational method based on probability and statistical theory methods and is widely used in chemistry and various natural sciences. Monte Carlo simulation can use the PK parameters of antimicrobial drugs in the human body, combined with the MIC distribution of bacteria, and PK / PD indicators as target values to simulate the probability of reaching the target for several clinical "cases", providing a reference for the optimization of clinical regimens. It has been widely used at home and abroad. PK / PD indicators are an important basis for dose selection. The area under the concentration-time curve (AUC) / MIC or Cmax / MIC can be used as PK / PD indicators to evaluate efficacy. Tigecycline is a time-dependent antimicrobial drug. When administered intravenously, AUC / MIC is the best PK / PD indicator for predicting its clinical and microbiological efficacy, and has a reliable correlation with clinical efficacy. However, due to the existence of the blood-brain barrier, the steady-state cerebrospinal fluid concentration of conventional or doubled doses of tigecycline cannot play a bactericidal role when administered intravenously, resulting in a small relationship between PK and blood drug concentration during intraventricular injection. The best PK / PD indicators for predicting its clinical and microbiological efficacy during intravenous administration are not applicable to intraventricular injection.
[0006] Therefore, there is an urgent need to develop a method using PK / PD indicators to evaluate the effectiveness of tigecycline intraventricular injection regimen for intracranial infection. Summary of the invention
[0007] In view of this, in order to solve this problem, the present invention first determines the PK / PD index for predicting the clinical and microbiological efficacy of intraventricular injection; at the same time, the present invention uses the PK / PD index to evaluate the effectiveness of the dosing regimen for a specific minimum inhibitory concentration.
[0008] In order to achieve the above object, the present invention adopts the following technical solution:
[0009] The method for evaluating the effectiveness of intraventricular injection of tigecycline based on Monte Carlo simulation is evaluated by combining Monte Carlo simulation with PK / PD model, including the following steps:
[0010] (1) Determine the PK / PD indicators, calculation formulas and target values for intraventricular injection
[0011] The PK / PD index is fCmax / MIC, and the calculation formula is as follows:
[0012]
[0013] fCmax is the peak concentration of free drug in cerebrospinal fluid, Vss is the apparent volume of distribution at steady state, Dose is the dose administered by intraventricular injection in 24 h, MIC is the minimum inhibitory concentration, and f is the fraction of free drug;
[0014] fCmax / MIC≥8 is the target value of PK / PD index for the effective treatment of intracranial infection by intraventricular injection of tigecycline;
[0015] (2) Monte Carlo simulation was performed on different intraventricular injection dosing regimens of tigecycline. Based on the fCmax / MIC results obtained by the simulation, the probability of different dosing regimens reaching the PK / PD target value at each specific MIC, i.e., PTA, was calculated. Then, the expected probability of different dosing regimens reaching the PK / PD target value for the pathogen population, i.e., CFR, was calculated. Dosing regimens with CFR ≥ 90% or PTA ≥ 90% were considered effective.
[0016] Preferably, fCmax / MIC≥8 is the effective PK / PD indicator target value for intraventricular injection of tigecycline in the treatment of intracranial infection of pan-drug-resistant Acinetobacter baumannii XDRAB.
[0017] Preferably, the intraventricular injection dosage regimen of tigecycline includes: 2 mg / every 12 hours, 3 mg / every 12 hours, 4 mg / every 12 hours, 5 mg / every 12 hours, 6 mg / every 12 hours, 10 mg / every 12 hours, and the drug concentrations are 0.5 mg / mL and 1.0 mg / mL, respectively, and the number of times is 1 time.
[0018] Preferably, WHONET software is used to calculate the MIC distribution of XDRAB; Oracle Crystalball 11.1.24 software is used to perform Monte Carlo simulation on different intraventricular injection regimens of tigecycline
[0019] Preferably, the effective dosing regimen includes: when the MIC is 2 mg / L, a 2 mg / every 12 hours dosing regimen is selected, when the MIC is 4 mg / L, a 3 mg / every 12 hours dosing regimen is selected, and when the MIC is 8 mg / L, a 5 mg / every 12 hours dosing regimen is selected, and the drug concentration does not exceed 1 mg / mL.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] 1. Innovation of research methods: The present invention uses MCS combined with PK / PD model to evaluate the application of intraventricular injection dosing regimen in intracranial infection.
[0022] 2. Innovation of research theory: Tigecycline is a time-dependent antibiotic. The best PK / PD index for predicting its clinical and microbiological efficacy when administered intravenously is AUC / MIC. However, due to the existence of the blood-brain barrier, the steady-state cerebrospinal fluid concentrations of conventional doses and doubled doses administered via intravenous administration cannot play a bactericidal role. The relationship between the PK and blood drug concentrations of intraventricular injection is relatively small. The PK / PD index of intravenous administration is not suitable for intraventricular injection. Therefore, the present invention proposes to use fCmax / MIC as the best PK / PD index for predicting its clinical and microbiological efficacy when administered via intraventricular injection.
[0023] 3. Innovation of research framework: Research reports on the treatment of intracranial infection via intraventricular injection are all case reports with inconsistent dosing regimens. The present invention adopts a retrospective case collection and Monte Carlo simulation framework model, uses retrospective clinical data to simulate data, and evaluates and screens the best dosing regimen through simulated data.
[0024] 4. Recommended effective dosing regimen for intraventricular injection: When the MIC is 2 mg / L, use a 2 mg / every 12 hours dosing regimen; when the MIC is 4 mg / L, use a 3 mg / every 12 hours dosing regimen; when the MIC is 8 mg / L, use a 5 mg / every 12 hours dosing regimen. The drug concentration should not exceed 1 mg / mL. DETAILED DESCRIPTION
[0025] The following describes embodiments of the present invention, which are exemplary and intended to be used to explain the present invention, but are not to be construed as limiting the present invention.
[0026] Example 1
[0027] 1. Determine the research subjects: patients with intracranial infection of pan-drug-resistant Acinetobacter baumannii (XDRAB).
[0028] 2. Establish inclusion and exclusion criteria: The inclusion criteria are: (1) meeting the diagnostic criteria for intracranial infection in the "Chinese Expert Consensus on the Diagnosis and Treatment of Central Nervous System Infection in Neurosurgery (2021 Edition)"; (2) the pathogen isolated from the cerebrospinal fluid specimen is XDRAB; (3) XDRAB is Acinetobacter baumannii that is insensitive to all other types of antimicrobial drugs except tigecycline and polymyxin 1-2. Exclusion criteria are: (1) multiple pathogens are isolated from the cerebrospinal fluid specimen; (2) the cerebrospinal fluid specimen is suspected to be contaminated.
[0029] 3. Design of intraventricular injection dosage regimen: 2 mg / every 12 hours, 3 mg / every 12 hours, 4 mg / every 12 hours, 5 mg / every 12 hours, 6 mg / every 12 hours, 10 mg / every 12 hours, the drug concentrations are 0.5 mg / mL and 1.0 mg / mL respectively, and the number of times is 1 time.
[0030] 4. Determine the PK / PD indicators, calculation formula and target value for intraventricular injection:
[0031] The PK / PD index is fCmax / MIC. The calculation formula of fCmax / MIC is determined by referring to the general calculation method of concentration-dependent antimicrobial drugs. The calculation formula of fCmax / MIC is as follows:
[0032]
[0033] Note: fCmax is the peak concentration of free drug in cerebrospinal fluid, Vss is the apparent distribution volume at steady state, Dose is the 24-hour intraventricular injection dose, MIC is the minimum inhibitory concentration, and f is the free drug fraction.
[0034] Target value: aminoglycosides, quinolones and other concentration-dependent antimicrobial drugs are used to treat XDRAB with fC max / MIC≥8 is taken as the clinical efficacy target value of the PK / PD index. Therefore, fCmax / MIC≥8 is set as the effective target value of the PK / PD index for intraventricular injection of tigecycline in the treatment of intracranial infection of XDRAB.
[0035] 6. Data processing software: WHONET software (www.WHONET.org.cn) was used to statistically analyze the MIC distribution of XDRAB. Oracle Crystalball 11.1.24 software (www.oracle.com) was used to perform 10,000 Monte Carlo simulations of different intraventricular injection dosing regimens of tigecycline. The fCmax / MIC results were obtained based on the simulations, and the probabilities of different dosing regimens reaching the target values at each specific MIC, i.e., PTA, were calculated. Then, the expected probabilities of different dosing regimens reaching the fCmax / MIC target values for the pathogen population, i.e., CFR, were calculated.
[0036] 7. Scheme screening and evaluation: Select CFR ≥ 90% or PTA ≥ 90% as an effective dosing regimen. The effective dosing regimen is: when the MIC is 2 mg / L, use a 2 mg / 12 hour dosing regimen; when the MIC is 4 mg / L, use a 3 mg / 12 hour dosing regimen; when the MIC is 8 mg / L, use a 5 mg / 12 hour dosing regimen; the drug concentration should not exceed 1 mg / mL.
[0037] Two patients with intracranial infection of XDRAB (MIC=4mg / L) were given a regimen of 0.5mg / mL, a single dose of 3mg, and two injections per day, and a regimen of 1mg / mL, a single dose of 3mg, and two injections per day. The clinical results showed that both regimens were effective, and the time to effectiveness and cure time when the drug concentration was 1mg / mL were both shorter than those when the drug concentration was 0.5mg / mL.
[0038] The above two patients with intracranial infection were both treated with intravenous medication without success, and then switched to intraventricular injection of tigecycline, which showed clinical effectiveness.
[0039] In order to further demonstrate the beneficial effects of the present invention and to better understand the present invention, the following comparative examples are used to further illustrate the technical features disclosed in the present invention, but they should not be construed as limiting the present invention. Other improvements made by those skilled in the art based on the above invention content without inventive work are also considered to fall within the scope of protection of the present invention.
[0040] The above description of the disclosed embodiments enables those skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.
[0041] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some of the technical features may be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for evaluating the effectiveness of intraventricular injection of tigecycline based on Monte Carlo simulation, characterized in that: The evaluation was performed by Monte Carlo simulation combined with PK / PD model, including the following steps: (1) Determine the PK / PD indicators, calculation formulas and target values for intraventricular injection The PK / PD index is fCmax / MIC, and the calculation formula is as follows: f max is the peak concentration of free drug in cerebrospinal fluid, Vss is the apparent volume of distribution at steady state, Dose is the dose administered by intraventricular injection for 24 h, MIC is the minimum inhibitory concentration, and f is the fraction of free drug; f max / MIC≥8 is the target value of PK / PD index for the effective treatment of intracranial infection by intraventricular injection of tigecycline; (2) Monte Carlo simulation was performed on different intraventricular injection regimens of tigecycline, and fC was obtained based on the simulation. max / MIC results, calculate the probability of different dosing regimens reaching the PK / PD target value at each specific MIC, that is, PTA; then calculate the expected probability of different dosing regimens reaching the PK / PD target value for the pathogen population, that is, CFR; the dosing regimen with CFR ≥ 90% or PTA ≥ 90% is an effective dosing regimen.
2. The method for evaluating the effectiveness of intraventricular injection of tigecycline based on Monte Carlo simulation according to claim 1, characterized in that: f max / MIC≥8 is the effective PK / PD target value for intraventricular injection of tigecycline in the treatment of intracranial infection with pan-drug-resistant Acinetobacter baumannii XDRAB.
3. The method for evaluating the effectiveness of intraventricular injection of tigecycline based on Monte Carlo simulation according to claim 1, characterized in that: The intraventricular injection dosage regimen of tigecycline includes: 2 mg / every 12 hours, 3 mg / every 12 hours, 4 mg / every 12 hours, 5 mg / every 12 hours, 6 mg / every 12 hours, and 10 mg / every 12 hours, with drug concentrations of 0.5 mg / mL and 1.0 mg / mL, respectively, and the number of times is 1 time.
4. The method for evaluating the effectiveness of intraventricular injection of tigecycline based on Monte Carlo simulation according to claim 1, characterized in that: WHONET software was used to statistically analyze the MIC distribution of XDRAB; Oracle Crystal ball11.1.24 software was used to perform Monte Carlo simulation of different intraventricular injection regimens of tigecycline.
5. The method for evaluating the effectiveness of intraventricular injection of tigecycline based on Monte Carlo simulation according to claim 1, characterized in that: The effective dosing regimen includes: when the MIC is 2 mg / L, a 2 mg / every 12 hours dosing regimen is selected; when the MIC is 4 mg / L, a 3 mg / every 12 hours dosing regimen is selected; when the MIC is 8 mg / L, a 5 mg / every 12 hours dosing regimen is selected, and the drug concentration does not exceed 1 mg / mL.
